Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including the nationâs leading ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first. Source
No articles found.
OrthoPediatrics currently markets greater than 30 surgical systems that serve thre...
OrthoPediatrics currently markets greater than ...
Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing nove...
Provention Bio, Inc. is a clinical-stage biopha...
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...
Trillium Therapeutics Inc. is a clinical stage ...
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedica...
Global Blood Therapeutics, Inc. (GBT) is a clin...
At Bellerophon Therapeutics, we aim to transform the lives of people suffering fro...
At Bellerophon Therapeutics, we aim to transfor...
Join the National Investor Network and get the latest information with your interests in mind.